FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast CancerJulia A. Beaver, Patricia Cortazar, Joyce Z. Crich et al.|Clinical Cancer Research|2015Cited by 377
First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast CancerLaleh Amiri‐Kordestani, Patricia Cortazar, Suparna Wedam et al.|Clinical Cancer Research|2014Cited by 153
First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast CancerGideon M. Blumenthal, Richard Pazdur, Nancy S. Scher et al.|Clinical Cancer Research|2013Cited by 120
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Richard Pazdur, Erik Bloomquist et al.|Clinical Cancer Research|2018Cited by 115
Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval SummaryPaul G. Kluetz, Richard Pazdur, Yang‐Min Ning et al.|Clinical Cancer Research|2013Cited by 62